Correction: A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients
Chiara Pane, Vincenzo Di Stefano, Nunzia Cuomo, Alessio Sarnataro, Claudia Vinciguerra, Liliana Bevilacqua, Filippo Brighina, Nicasio Rini, Giorgia Puorro, Angela Marsili, Matteo Garibaldi, Laura Fionda, Francesco Saccà
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsMyasthenia Gravis and Thymoma · Cancer Treatment and Pharmacology · Peripheral Neuropathies and Disorders
Correction: Journal of Neurology (2024) 271:6209–6219 10.1007/s00415-024-12588-7
In the original version of this article, tables 1 and 2 footnotes were inadvertently omitted.
Table 1 footnote should have read
AChR-Ab+ = anti-acetylcholine receptor antibody positive; Py = Pyridostigmine; CS = Corticosteroids; NSIST = Non-steroidal Immunosuppressant; IVIg = Intravenous Immunoglobulins; PLEX = Plasmapheresis; MGADL = Myasthenia Gravis Activities of Daily Living scale; QMG = Myasthenia Gravis quantitative scale. ^*^6 patients treated with Efgartigimod were seronegative, and 3 were Ab-MuSK+; ^$^p value refers to the distribution of the total number of NSISTs across treatment groups; ^#^p value refers to Eculizumab vs Efgartigimod AChRAb+ only patients
Table 2 footnote should have read
Intertreatment distance is shown as the distance in days between the first Efgartigimod administration of one cycle to the first administration of the next cycle. Cycles after the 6th are not shown for limited number of patients
The original article has been corrected.